BioLattice, a company focused on developing tissue repair solutions, has secured $575,000 in its latest funding round. The investment will support the advancement of its innovative approach to addressing critical needs in regenerative medicine, particularly in the field of ophthalmology.
The company is dedicated to developing engineered cornea as a viable alternative to donor tissue for full-thickness cornea transplants. This initiative addresses a significant global health challenge, as approximately 2 million people worldwide suffer from corneal blindness annually. Currently, only about 200,000 individuals receive vision restoration through cornea transplants each year, largely due to a severe shortage of donor tissue. BioLattice aims to bridge this gap, as there is no existing first-line alternative to donor cornea tissue for these procedures.
This capital infusion underscores investor confidence in BioLattice's technology and its potential to revolutionize corneal repair. The $575,000 raised will be strategically deployed to accelerate research and development efforts, further refine its engineered cornea product, and expand its operational capabilities. The company plans to use the funds to advance its proprietary technology through crucial development milestones, moving closer to clinical application.
BioLattice's successful funding round positions it to make substantial progress in its mission to provide a true alternative to donor cornea. The company anticipates that this investment will enable it to scale its development efforts and ultimately improve access to vital vision restoration solutions for millions globally, driving its growth trajectory in the regenerative medicine sector.
